GLMD.US Galmed Pharmaceuticals Ltd

Biotechnology USA Stocks
4.63 USD
Close of Oct 2, 2026
0.4112 5.45
Market cap
USD 4.95M
P/E
-
P/B
0.23x
ROE
-118.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is GLMD.US undervalued?

Graham number

The Graham number of Galmed Pharmaceuticals Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Galmed Pharmaceuticals Ltd fundamental analysis

No fundamental analysis for Galmed Pharmaceuticals Ltd yet.

Galmed Pharmaceuticals Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Galmed Pharmaceuticals Ltd

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol t…

Full company profile